

Leslie Citrome

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5314670/leslie-citrome-publications-by-year.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

390
papers

11,889
citations

55
h-index

90
g-index

518
ext. papers

14,158
ext. citations

3.6
avg, IF

7.34
L-index

#	Paper	IF	Citations
390	Perceived Burdens and Educational Needs of Caregivers of People with Schizophrenia: Results of a National Survey Study.. <i>Patient Preference and Adherence</i> , 2022 , 16, 159-168	2.4	0
389	Management of Schizophrenia with Long-Acting Injectable Antipsychotic Medications: An Assessment of the Educational Needs of Clinicians.. <i>Neuropsychiatric Disease and Treatment</i> , 2022 , 18, 111-123	3.1	0
388	Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder: A Randomized Clinical Trial.. <i>JAMA - Journal of the American Medical Association</i> , 2022 , 327, 727-736	27.4	3
387	Effect of the HP-3070 Transdermal System (Secuado) on Symptoms of Hostility in Adults with Schizophrenia.. <i>CNS Spectrums</i> , 2022 , 27, 241	1.8	
386	Excess healthcare resource utilization and healthcare costs among privately and publicly insured patients with major depressive disorder and acute suicidal ideation or behavior in the United States. <i>Journal of Affective Disorders</i> , 2022 , 311, 303-310	6.6	1
385	Agitation in schizophrenia: origins and evidence-based treatment. <i>Current Opinion in Psychiatry</i> , 2021 , 34, 216-221	4.9	2
384	Health care resource use, short-term disability days, and costs associated with states of persistence on antidepressant lines of therapy. <i>Journal of Medical Economics</i> , 2021 , 24, 1299-1308	2.4	
383	Tardive Dyskinesia in Older Persons Taking Antipsychotics. <i>Neuropsychiatric Disease and Treatment</i> , 2021 , 17, 3127-3134	3.1	1
382	Pharmacokinetic Profile of the Asenapine Transdermal System (HP-3070). <i>Journal of Clinical Psychopharmacology</i> , 2021 , 41, 286-294	1.7	7
381	Using Item 8 of the Abnormal Involuntary Movement Scale (AIMS) to Assess Improvement in Patients with Tardive Dyskinesia. <i>CNS Spectrums</i> , 2021 , 26, 152	1.8	
380	A Combination of Olanzapine and Samidorphan in Adults with Schizophrenia and Bipolar I Disorder: Overview of Clinical Data. <i>CNS Spectrums</i> , 2021 , 26, 170	1.8	0
379	Assessing the Benefit-Risk Ratio of Approved Treatments for Bipolar Depression Using Likelihood to be Helped or Harmed (LHH) Analyses. <i>CNS Spectrums</i> , 2021 , 26, 146	1.8	
378	Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel Recommendations. <i>Neuropsychiatric Disease and Treatment</i> , 2021 , 17, 1589-1597	3.1	2
377	Cariprazine and akathisia, restlessness, and extrapyramidal symptoms in patients with bipolar depression. <i>Journal of Affective Disorders</i> , 2021 , 288, 191-198	6.6	2
376	Lemborexant for the Treatment of Insomnia: Direct and Indirect Comparisons With Other Hypnotics Using Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed. <i>Journal of Clinical Psychiatry</i> , 2021 , 82,	4.6	1
375	Benefit-Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm. <i>Advances in Therapy</i> , 2021 , 38, 4442-4460	4.1	0
374	Binge Eating Disorder: A Psychiatrist's Commentary on Clinical Considerations. <i>Clinical Therapeutics</i> , 2021 , 43, 7-16	3.5	0

373	Does antipsychotic combination therapy reduce the risk of hospitalization in schizophrenia?. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 635-646	4	3
372	Real-World Medication Treatment Patterns for Long-Term Care Residents with Dementia-Related Psychosis. <i>Gerontology and Geriatric Medicine</i> , 2021 , 7, 23337214211016565	2.3	1
371	Long-acting injectable antipsychotics: what, when, and how. <i>CNS Spectrums</i> , 2021 , 26, 118-129	1.8	9
370	Advances in the Treatment of Chronic Insomnia: A Narrative Review of New Nonpharmacologic and Pharmacologic Therapies. <i>Neuropsychiatric Disease and Treatment</i> , 2021 , 17, 2549-2566	3.1	4
369	Prevalence of Pre-existing Conditions Relevant for Adverse Events and Potential Drug-Drug Interactions Associated with Augmentation Therapies Among Patients with Treatment-Resistant Depression. <i>Advances in Therapy</i> , 2021 , 38, 4900-4916	4.1	1
368	An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2021 , 17, 2885-2904	3.1	0
367	Long-acting injectable antipsychotics: what, when, and how - CORRIGENDUM. <i>CNS Spectrums</i> , 2021 , 1	1.8	3
366	Asenapine: an atypical antipsychotic with atypical formulations. <i>Therapeutic Advances in Psychopharmacology</i> , 2021 , 11, 20451253211035269	4.9	3
365	Specific Anti-hostility Effects of Atypical Antipsychotics in Persons with Schizophrenia: From Clozapine to Cariprazine. <i>Harvard Review of Psychiatry</i> , 2021 , 29, 20-34	4.1	3
364	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels.. <i>Pharmacopsychiatry</i> , 2021 , 55,	2	11
363	Intravenous brexanolone for postpartum depression: what it is, how well does it work, and will it be used?. <i>Therapeutic Advances in Psychopharmacology</i> , 2020 , 10, 2045125320968658	4.9	6
362	Appraising esketamine nasal spray for the management of treatment-resistant depression in adults: Number needed to treat, number needed to harm, and likelihood to be helped or harmed. <i>Journal of Affective Disorders</i> , 2020 , 271, 228-238	6.6	7
361	The treatment of acute agitation associated with schizophrenia or bipolar disorder: investigational drugs in early stages of their clinical development, and their clinical context and potential place in therapy. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 245-257	5.9	3
360	145 Incidence and Characteristics of Akathisia and Restlessness During Cariprazine Treatment for Bipolar I Disorder. <i>CNS Spectrums</i> , 2020 , 25, 292-292	1.8	
359	146 Efficacy and Safety of the Asenapine Transdermal Patch, HP-3070, for Schizophrenia: A Phase 3, Randomized, Placebo-Controlled, Inpatient Study. <i>CNS Spectrums</i> , 2020 , 25, 293-293	1.8	1
358	144 Esketamine Nasal Spray for Management of Treatment-Resistant Depression: Number Needed to Treat, Number Needed to Harm, Likelihood to be Helped/Harmed. <i>CNS Spectrums</i> , 2020 , 25, 291-292	1.8	
357	168 Effect of Dasotraline on Body Weight in Patients with Binge-Eating Disorder. <i>CNS Spectrums</i> , 2020 , 25, 307-307	1.8	0
356	169 Dasotraline for Treatment of Adults with Binge-Eating Disorder: Effect on Binge-related Obsessions and Compulsions. <i>CNS Spectrums</i> , 2020 , 25, 307-308	1.8	1

355	433 - Burden of Disease Associated with Dementia-related Psychosis and Dementia-related Agitation & Aggression Using a National Long-term Care US Database. <i>International Psychogeriatrics</i> , 2020 , 32, 149-150	3.4	
354	A Modified Delphi Consensus Study of the Screening, Diagnosis, and Treatment of Tardive Dyskinesia. <i>Journal of Clinical Psychiatry</i> , 2020 , 81,	4.6	4
353	Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. <i>Journal of Clinical Psychiatry</i> , 2020 , 81,	4.6	39
352	Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder: A Phase 2, Randomized Clinical Trial. <i>Journal of Clinical Psychiatry</i> , 2020 , 81,	4.6	6
351	Efficacy and Safety of HP-3070, an Asenapine Transdermal System, in Patients With Schizophrenia: A Phase 3, Randomized, Placebo-Controlled Study. <i>Journal of Clinical Psychiatry</i> , 2020 , 82,	4.6	4
350	Revisiting Tardive Dyskinesia: Focusing on the Basics of Identification and Treatment. <i>Journal of Clinical Psychiatry</i> , 2020 , 81,	4.6	5
349	Psychopharmacology of Violent Behavior Among People with Severe Mental Disorders. <i>Comprehensive Approach To Psychiatry</i> , 2020 , 253-268	0.7	
348	New discoveries for an old drug: a review of recent olanzapine research. <i>Postgraduate Medicine</i> , 2020 , 132, 80-90	3.7	20
347	Examining the safety, efficacy, and patient acceptability of inhaled loxapine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. <i>Neuropsychiatric Disease and Treatment</i> , 2019 , 15, 2273-2283	3.1	7
346	A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future. <i>Neuropsychiatric Disease and Treatment</i> , 2019 , 15, 2559-2569	3.1	21
345	Disclosures and Conflicts of Interest: Solving the Riddle, Wrapped in a Mystery, Inside an Enigma. <i>Clinical Therapeutics</i> , 2019 , 41, 2643-2655	3.5	1
344	Brexipiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy. <i>Neuropsychiatric Disease and Treatment</i> , 2019 , 15, 247-257	3.1	87
343	Binge eating disorder revisited: what's new, what's different, what's next. <i>CNS Spectrums</i> , 2019 , 24, 4-13	1.8	26
342	41 A Modified Delphi Consensus Approach to Clinical Guidelines for Tardive Dyskinesia. <i>CNS Spectrums</i> , 2019 , 24, 197-198	1.8	
341	Cariprazine for bipolar depression: What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. <i>International Journal of Clinical Practice</i> , 2019 , 73, e13397	2.9	9
340	Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm. <i>Neuropsychiatric Disease and Treatment</i> , 2019 , 15, 2639-2646	3.1	3
339	Olanzapine Plus Samidorphan in Subjects with Schizophrenia and Comorbid Alcohol Use Disorder: Rationale and Design for a Phase II, Double-blind, Randomized Study. <i>Innovations in Clinical Neuroscience</i> , 2019 , 16, 15-21	1	3
338	Prevalence, treatment patterns, and stay characteristics associated with hospitalizations for major depressive disorder. <i>Journal of Affective Disorders</i> , 2019 , 249, 378-384	6.6	21

337	Patches: Established and Emerging Transdermal Treatments in Psychiatry. <i>Journal of Clinical Psychiatry</i> , 2019 , 80,	4.6	10
336	C.10.04 Exploring treatment decision-making for patients with schizophrenia. <i>European Neuropsychopharmacology</i> , 2019 , 29, S596-S597	1.2	
335	Effect of Brexpiprazole on Agitation and Hostility in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies. <i>Journal of Clinical Psychopharmacology</i> , 2019 , 39, 597-603	1.7	7
334	Resistance is not futile: treatment-refractory schizophrenia - overview, evaluation and treatment. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 11-24	4	13
333	Reprint of: Clinical management of tardive dyskinesia: Five steps to success. <i>Journal of the Neurological Sciences</i> , 2018 , 389, 61-66	3.2	2
332	Lisdexamfetamine: chemistry, pharmacodynamics, pharmacokinetics, and clinical efficacy, safety, and tolerability in the treatment of binge eating disorder. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 229-238	5.5	18
331	Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective. <i>Expert Review of Neurotherapeutics</i> , 2018 , 18, 323-332	4.3	9
330	Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale-supportive analyses from a Phase 3 study. <i>CNS Spectrums</i> , 2018 , 23, 284-290	1.8	8
329	Vesicular monoamine transporter type 2 inhibition can lead to effective and tolerable management of tardive dyskinesia. <i>Evidence-Based Mental Health</i> , 2018 , 21, e12	11.1	
328	Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia-Key Differences in Pathophysiology and Clinical Management. <i>Neurology and Therapy</i> , 2018 , 7, 233-248	4.6	41
327	Relationships between clinical scales and binge eating days in adults with moderate to severe binge eating disorder in two Phase III studies. <i>Neuropsychiatric Disease and Treatment</i> , 2018 , 14, 537-546	3.1	5
326	Sustained-Release Risperidone via Subcutaneous Injection: A Systematic Review of RBP-7000 (PERSERIS) for the Treatment of Schizophrenia. <i>Clinical Schizophrenia and Related Psychoses</i> , 2018 , 12, 130-141	1.6	86
325	Inaccurate Prescribing Warnings in Electronic Medical Record Systems: Results From an American Society of Clinical Psychopharmacology Membership Survey. <i>Journal of Clinical Psychiatry</i> , 2018 , 80,	4.6	1
324	Pimavanserin for the treatment of Parkinson's disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed. <i>CNS Spectrums</i> , 2018 , 23, 228-238	1.8	9
323	Psychiatric commentary addressing the article titled "Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus". <i>CNS Spectrums</i> , 2018 , 23, 355-357	1.8	
322	152 Pimavanserin for the Treatment of Parkinson's Disease Psychosis: Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed. <i>CNS Spectrums</i> , 2018 , 23, 94-95	1.8	
321	Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy. <i>Neuropsychiatric Disease and Treatment</i> , 2018 , 14, 2563-2577	3.1	19
320	Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA. <i>ClinicoEconomics and Outcomes Research</i> , 2018 , 10, 443-456	1.7	9

319	Investigational drugs in recent clinical trials for treatment-resistant depression. <i>Expert Review of Neurotherapeutics</i> , 2017 , 17, 593-609	4.3	46
318	Measurement of agitation and aggression in adult and aged neuropsychiatric patients: review of definitions and frequently used measurement scales. <i>CNS Spectrums</i> , 2017 , 22, 407-414	1.8	13
317	Activating and Sedating Adverse Effects of Second-Generation Antipsychotics in the Treatment of Schizophrenia and Major Depressive Disorder: Absolute Risk Increase and Number Needed to Harm. <i>Journal of Clinical Psychopharmacology</i> , 2017 , 37, 138-147	1.7	49
316	Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. <i>International Journal of Clinical Practice</i> , 2017 , 71, e12964	2.9	19
315	Efficacy of lurasidone in the treatment of agitation: A post hoc analysis of five short-term studies in acutely ill patients with schizophrenia. <i>General Hospital Psychiatry</i> , 2017 , 47, 75-82	5.6	7
314	Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2017 , 37, 289-295	1.7	29
313	Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. <i>American Journal of Psychiatry</i> , 2017 , 174, 216-229	11.9	408
312	Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. <i>International Journal of Clinical Practice</i> , 2017 , 71, e13030	2.9	15
311	Effects of asenapine on agitation and hostility in adults with acute manic or mixed episodes associated with bipolar I disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2017 , 13, 2955-2963	3.1	7
310	Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications. <i>Expert Review of Neurotherapeutics</i> , 2017 , 17, 1029-1043	4.3	19
309	Clinical management of tardive dyskinesia: Five steps to success. <i>Journal of the Neurological Sciences</i> , 2017 , 383, 199-204	3.2	10
308	Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 493-503	6.2	29
307	Binge-Eating Disorder and Comorbid Conditions: Differential Diagnosis and Implications for Treatment. <i>Journal of Clinical Psychiatry</i> , 2017 , 78 Suppl 1, 9-13	4.6	15
306	Psychopharmacological Approaches to Aggression and Violence in Adults with Severe Mental Illness: What Works? What Works Best? 2017 , 1-15		
305	Dr Correll and Colleagues Reply. <i>Journal of Clinical Psychiatry</i> , 2017 , 78, e1062	4.6	1
304	Sensitive and Personalized Determinations of Likelihood of Being Helped or Harmed. <i>Journal of Clinical Psychiatry</i> , 2017 , 78, e554	4.6	
303	Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective. <i>BMJ, The</i> , 2016 , 355, i5078	5.9	53
302	More inclusive bipolar mixed depression definitions by requiring fewer non-overlapping mood elevation symptoms. <i>Acta Psychiatrica Scandinavica</i> , 2016 , 134, 189-98	6.5	8

301	Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies. <i>European Psychiatry</i> , 2016 , 31, 13-9	6	16
300	Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 169-86	3.8	22
299	Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 921-36	4	22
298	Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed. <i>Journal of Affective Disorders</i> , 2016 , 196, 225-33	6.6	41
297	Pharmaceutical Innovation in the Treatment of Schizophrenia and Mental Disorders Compared with Other Diseases. <i>Innovations in Clinical Neuroscience</i> , 2016 , 13, 17-25	1	12
296	Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist. <i>Clinical Schizophrenia and Related Psychoses</i> , 2016 , 10, 109-19	1.6	29
295	Guide to the Management of Clozapine-Related Tolerability and Safety Concerns. <i>Clinical Schizophrenia and Related Psychoses</i> , 2016 , 10, 163-177	1.6	58
294	Brexipiprazole for the Treatment of Schizophrenia: A Review of this Novel Serotonin-Dopamine Activity Modulator. <i>Clinical Schizophrenia and Related Psychoses</i> , 2016 , 9, 177-86	1.6	21
293	A Guide to the Management of Clozapine-Related Tolerability and Safety Concerns. <i>Clinical Schizophrenia and Related Psychoses</i> , 2016 ,	1.6	3
292	The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence. <i>Journal of Clinical Psychiatry</i> , 2016 , 77, 1-24	4.6	173
291	The effect of cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trials. <i>Journal of Clinical Psychiatry</i> , 2016 , 77, 109-15	4.6	23
290	Lurasidone Dose Escalation in Early Nonresponding Patients With Schizophrenia: A Randomized, Placebo-Controlled Study. <i>Journal of Clinical Psychiatry</i> , 2016 , 77, 1672-1680	4.6	22
289	Characteristics of binge eating disorder in relation to diagnostic criteria. <i>Neuropsychiatric Disease and Treatment</i> , 2016 , 12, 2213-23	3.1	21
288	Schizophrenia relapse, patient considerations, and potential role of lurasidone. <i>Patient Preference and Adherence</i> , 2016 , 10, 1529-37	2.4	8
287	Managing Agitation Associated with Schizophrenia and Bipolar Disorder in the Emergency Setting. <i>Western Journal of Emergency Medicine</i> , 2016 , 17, 165-72	3.3	32
286	Categorical improvements in disease severity in patients with major depressive disorder treated with vilazodone: post hoc analysis of four randomized, placebo-controlled trials. <i>Neuropsychiatric Disease and Treatment</i> , 2016 , 12, 3073-3081	3.1	
285	Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia. <i>International Clinical Psychopharmacology</i> , 2016 , 31, 69-75	2.2	19
284	The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study. <i>International Clinical Psychopharmacology</i> , 2016 , 31, 192-201	2.2	42

283	More inclusive bipolar mixed depression definition by permitting overlapping and non-overlapping mood elevation symptoms. <i>Acta Psychiatrica Scandinavica</i> , 2016 , 134, 199-206	6.5	12
282	Psychiatric Disorders and Diabetes 2016 , 840-858		2
281	NNT and NNH remain helpful in evidence-based medicine. <i>British Journal of Psychiatry</i> , 2016 , 209, 262-3	5.4	2
280	Emerging pharmacological therapies in schizophrenia: what's new, what's different, what's next?. <i>CNS Spectrums</i> , 2016 , 21, 1-12	1.8	12
279	Which role for brexpiprazole, a new dopamine D2 partial agonist, in the treatment of schizophrenia?. <i>Evidence-Based Mental Health</i> , 2016 , 19, e6	11.1	1
278	Investigational drugs for treating agitation in persons with dementia. <i>Expert Opinion on Investigational Drugs</i> , 2016 , 25, 973-83	5.9	21
277	Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies. <i>European Neuropsychopharmacology</i> , 2015 , 25, 1158-66	1.2	67
276	Preventing Violence in Patients with Schizophrenia. <i>Current Treatment Options in Psychiatry</i> , 2015 , 2, 182-191	3.1	4
275	Paliperidone Palmitate for Schizoaffective Disorder: A Review of the Clinical Evidence. <i>Neurology and Therapy</i> , 2015 , 4, 81-91	4.6	12
274	Evaluating the efficacy of vilazodone in achieving remission in patients with major depressive disorder: post-hoc analyses of a phase IV trial. <i>International Clinical Psychopharmacology</i> , 2015 , 30, 75-81 ^{2.2}		7
273	Patients' Preferences Related to Benefits, Risks, and Formulations of Schizophrenia Treatment. <i>Psychiatric Services</i> , 2015 , 66, 719-26	3.3	23
272	The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?. <i>Expert Review of Neurotherapeutics</i> , 2015 , 15, 1219-29	4.3	39
271	P.3.d.073 Cariprazine and the reduction of hostility associated with schizophrenia. <i>European Neuropsychopharmacology</i> , 2015 , 25, S523	1.2	
270	Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression. <i>BJPsych Bulletin</i> , 2015 , 39, 237-41	1.2	30
269	A primer on binge eating disorder diagnosis and management. <i>CNS Spectrums</i> , 2015 , 20 Suppl 1, 44-50; quiz 51	1.8	11
268	Cognitive impairment in schizophrenia: the great unmet need. <i>CNS Spectrums</i> , 2015 , 20 Suppl 1, 35-9; quiz 40	1.8	11
267	Lisdexamfetamine for binge eating disorder in adults: a systematic review of the efficacy and safety profile for this newly approved indication - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. <i>International Journal of Clinical Practice</i> , 2015 , 69, 410-21	2.9	76
266	Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. <i>International Journal of Clinical Practice</i> , 2015 , 69, 378-87	2.9	40

265	Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3. <i>Annals of Internal Medicine</i> , 2015 , 163, 461-4	8	207
264	Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation. <i>BMC Psychiatry</i> , 2015 , 15, 271	4.2	9
263	THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY SURVEY OF PSYCHOPHARMACOLOGISTS' PRACTICE PATTERNS FOR THE TREATMENT OF MOOD DISORDERS. <i>Depression and Anxiety</i> , 2015 , 32, 605-13	8.4	25
262	Lack of tolerable treatment options for patients with schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2015 , 11, 3095-104	3.1	15
261	Pharmacotherapy for bipolar depression: comparative efficacy and acceptability is in the eye of the beholder. <i>Evidence-Based Mental Health</i> , 2015 , 18, 88	11.1	0
260	Switching to iloperidone: An omnibus of clinically relevant observations from a 12-week, open-label, randomized clinical trial in 500 persons with schizophrenia. <i>Clinical Schizophrenia and Related Psychoses</i> , 2015 , 8, 183-95	1.6	6
259	Brexpiprazole: a new dopamine D ₂ receptor partial agonist for the treatment of schizophrenia and major depressive disorder. <i>Drugs of Today</i> , 2015 , 51, 397-414	2.5	20
258	Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014 , 10, 893-903	5.5	47
257	Asenapine review, part II: clinical efficacy, safety and tolerability. <i>Expert Opinion on Drug Safety</i> , 2014 , 13, 803-30	4.1	27
256	A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia. <i>Schizophrenia Research</i> , 2014 , 153, 160-8	3.6	13
255	Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study - ADDENDUM. <i>CNS Spectrums</i> , 2014 , 19, 466	1.8	3
254	Balancing benefits and harms of treatments for acute bipolar depression. <i>Journal of Affective Disorders</i> , 2014 , 169 Suppl 1, S24-33	6.6	37
253	Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. <i>CNS Spectrums</i> , 2014 , 19, 330-9	1.8	32
252	Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States. <i>Journal of Medical Economics</i> , 2014 , 17, 567-76	2.4	19
251	Psychiatrists' judgments about antipsychotic benefit and risk outcomes and formulation in schizophrenia treatment. <i>Psychiatric Services</i> , 2014 , 65, 1133-9	3.3	7
250	Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. <i>International Journal of Clinical Practice</i> , 2014 , 68, 1429-41	2.9	127
249	Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. <i>International Journal of Clinical Practice</i> , 2014 , 68, 60-82	2.9	45
248	A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation. <i>Acta Psychiatrica Scandinavica</i> , 2014 , 130, 61-8	6.5	47

247	Treatment of bipolar depression: making sensible decisions. <i>CNS Spectrums</i> , 2014 , 19 Suppl 1, 4-11; quiz 1-3, 12	1.8	11
246	Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. <i>CNS Spectrums</i> , 2014 , 19, 374-81	1.8	31
245	A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults. <i>Current Medical Research and Opinion</i> , 2014 , 30, 1629-41	2.5	28
244	Review: 15 antipsychotic drugs are more effective than placebo for the treatment of schizophrenia, but vary in their tolerability. <i>Evidence-Based Mental Health</i> , 2014 , 17, 9	11.1	2
243	The psychopharmacology of violence: making sensible decisions. <i>CNS Spectrums</i> , 2014 , 19, 411-8	1.8	43
242	Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. <i>Journal of Affective Disorders</i> , 2014 , 155, 20-7	6.6	45
241	The Sunshine Act and Transfers of Value: Impact on Non-industry Authorship. <i>Innovations in Clinical Neuroscience</i> , 2014 , 11, 14-6	1	1
240	Quantifying clinical relevance. <i>Innovations in Clinical Neuroscience</i> , 2014 , 11, 26-30	1	23
239	Beyond PubMed: Searching the "Grey Literature" for Clinical Trial Results. <i>Innovations in Clinical Neuroscience</i> , 2014 , 11, 42-6	1	5
238	Prevalence of pre-existing risk factors for adverse events associated with atypical antipsychotics among commercially insured and medicaid insured patients newly initiating atypical antipsychotics. <i>Current Drug Safety</i> , 2014 , 9, 227-35	1.4	8
237	Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains. <i>Journal of Clinical Psychiatry</i> , 2014 , 75 Suppl 1, 21-6	4.6	66
236	New Treatment Targets to Improve Symptoms in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2014 , 75, e22	4.6	2
235	Psicofarmacologia e terapia elettroconvulsivante 2014 , 271-289		
234	A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. <i>CNS Drugs</i> , 2013 , 27, 879-911	6.7	66
233	A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities. <i>Schizophrenia Research</i> , 2013 , 147, 241-52	3.6	68
232	Diagnoses associated with use of atypical antipsychotics in a commercial health plan: a claims database analysis. <i>Clinical Therapeutics</i> , 2013 , 35, 1867-75	3.5	20
231	Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013 , 9, 193-206	5.5	78
230	Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. <i>International Journal of Clinical Practice</i> , 2013 , 67, 1089-104	2.9	104

229	Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy. <i>Advances in Therapy</i> , 2013 , 30, 102-13	4.1	30
228	Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy. <i>Advances in Therapy</i> , 2013 , 30, 114-26	4.1	42
227	P.2.b.018 Post hoc analyses of levomilnacipran SR 40, 80, and 120 mg on functional outcomes in major depressive disorder. <i>European Neuropsychopharmacology</i> , 2013 , 23, S329	1.2	2
226	P.3.d.007 Efficacy of cariprazine on PANSS items and Marder factors: post hoc analysis of a double-blind, placebo-controlled trial in schizophrenia. <i>European Neuropsychopharmacology</i> , 2013 , 23, S461-S462	1.2	
225	Number needed to treat can be helpful: a response to Alphas et al. <i>European Neuropsychopharmacology</i> , 2013 , 23, 1656-7	1.2	1
224	Placing transdermal selegiline for major depressive disorder into clinical context: number needed to treat, number needed to harm, and likelihood to be helped or harmed. <i>Journal of Affective Disorders</i> , 2013 , 151, 409-417	6.6	15
223	Meta-guidelines for the management of patients with schizophrenia. <i>CNS Spectrums</i> , 2013 , 18, 150-162	1.8	46
222	Handbook of Treatment-resistant Schizophrenia 2013 ,		1
221	Number needed to harm can be clinically useful: a response to Safer and Zito. <i>Journal of Nervous and Mental Disease</i> , 2013 , 201, 1001-2	1.8	1
220	High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study. <i>Journal of Clinical Psychopharmacology</i> , 2013 , 33, 485-90	1.7	14
219	Review: Limited evidence on effects of haloperidol alone for rapid tranquillisation in psychosis-induced aggression. <i>Evidence-Based Mental Health</i> , 2013 , 16, 47	11.1	3
218	When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. <i>International Journal of Clinical Practice</i> , 2013 , 67, 407-11	2.9	121
217	New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia. <i>Expert Review of Neurotherapeutics</i> , 2013 , 13, 767-83	4.3	57
216	Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agents. <i>Therapeutics and Clinical Risk Management</i> , 2013 , 9, 235-45	2.9	27
215	Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. <i>Journal of Clinical Psychiatry</i> , 2013 , 74, 170-9	4.6	44
214	Incidence of cardiovascular outcomes and diabetes mellitus among users of second-generation antipsychotics. <i>Journal of Clinical Psychiatry</i> , 2013 , 74, 1199-206	4.6	24
213	A General Treatment Approach 2013 , 14-19		
212	Psychopharmacological Approaches 2013 , 37-56		

211 Somatic Treatments **2013**, 57-60

210 Adherence: The Great Masquerader of Treatment-Resistance **2013**, 20-28

209 Dosing of Antipsychotics: What Evidence Do We Use? **2013**, 29-33

208 Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. *International Journal of Clinical Practice*, **2012**, 66, 356-68 2.9 121

207 Antidepressants and the relief of osteoarthritic pain - findings from a study examining adjunctive duloxetine. *International Journal of Clinical Practice*, **2012**, 66, 431-3 2.9 6

206 Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials. *Human Psychopharmacology*, **2012**, 27, 24-32 2.3 14

205 Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability. *Expert Opinion on Drug Metabolism and Toxicology*, **2012**, 8, 873-88 5.5 21

204 A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia. *Expert Opinion on Pharmacotherapy*, **2012**, 13, 1545-73 4 47

203 Lurasidone for schizophrenia: what's different?. *Expert Review of Neurotherapeutics*, **2012**, 12, 265-73 4.3 10

202 Antidepressant therapy for pain associated with osteoarthritis. *PM and R*, **2012**, 4, 1024-5 2.2

201 Impact of the CATIE trial on antipsychotic prescribing. *Schizophrenia Research*, **2012**, 138, 295 3.6

200 Oral antipsychotic update: a brief review of new and investigational agents for the treatment of schizophrenia. *CNS Spectrums*, **2012**, 17 Suppl 1, 1-9 1.8 7

199 Lurasidone in schizophrenia: new information about dosage and place in therapy. *Advances in Therapy*, **2012**, 29, 815-25 4.1 30

198 On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not. *Expert Opinion on Pharmacotherapy*, **2012**, 13, 1599-613 4 21

197 Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder. *International Journal of Clinical Practice*, **2012**, 66, 318-25 2.9 26

196 Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. *International Clinical Psychopharmacology*, **2012**, 27, 165-76 2.2 76

195 A systematic review of duloxetine for osteoarthritic pain: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?. *Postgraduate Medicine*, **2012**, 124, 83-93 3.7 31

194 Trends in combination antipsychotic use among persons with commercial insurance: a data snapshot. *Innovations in Clinical Neuroscience*, **2012**, 9, 17-8 1

193	Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?. <i>Clinical Schizophrenia and Related Psychoses</i> , 2012 , 6, 76-85	1.6	28
192	Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis. <i>Schizophrenia Research</i> , 2011 , 131, 75-81	3.6	55
191	Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. <i>Clinical Drug Investigation</i> , 2011 , 31, 455-82	3.2	74
190	High dose quetiapine in the treatment of psychosis due to traumatic brain injury: a case report. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011 , 35, 280-1	5.5	5
189	Role of sublingual asenapine in treatment of schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2011 , 7, 325-39	3.1	21
188	A randomized, double-blind, parallel-group, fixed-dose, clinical trial of quetiapine at 600 versus 1200 mg/d for patients with treatment-resistant schizophrenia or schizoaffective disorder. <i>Journal of Clinical Psychopharmacology</i> , 2011 , 31, 160-8	1.7	25
187	Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. <i>International Journal of Clinical Practice</i> , 2011 , 65, 189-210	2.9	95
186	Does it work, will it work, and is it worth it? A call for papers (and reviewers) regarding effective treatments for psychiatric disorders. <i>International Journal of Clinical Practice</i> , 2011 , 65, 232-233	2.9	3
185	Aerosolised antipsychotic assuages agitation: inhaled loxapine for agitation associated with schizophrenia or bipolar disorder. <i>International Journal of Clinical Practice</i> , 2011 , 65, 330-40	2.9	26
184	Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions?. <i>Acta Psychiatrica Scandinavica</i> , 2011 , 123, 175-89	6.5	36
183	Olanzapine-fluoxetine combination for the treatment of bipolar depression. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 2751-8	4	13
182	Pharmacological management of acute and persistent aggression in forensic psychiatry settings. <i>CNS Drugs</i> , 2011 , 25, 1009-21	6.7	27
181	Drug safety evaluation of ziprasidone. <i>Expert Opinion on Drug Safety</i> , 2011 , 10, 437-48	4.1	19
180	Treatment-refractory schizophrenia: what is it and what has been done about it?. <i>Neuropsychiatry</i> , 2011 , 1, 325-347	1.8	8
179	Pathways to aggression in schizophrenia affect results of treatment. <i>Schizophrenia Bulletin</i> , 2011 , 37, 921-9	1.3	122
178	Schizoaffective disorder: a review of current research themes and pharmacological management. <i>CNS Drugs</i> , 2011 , 25, 317-31	6.7	18
177	lloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics. <i>Postgraduate Medicine</i> , 2011 , 123, 153-62	3.7	51
176	Psychopharmacology of aggression in schizophrenia. <i>Schizophrenia Bulletin</i> , 2011 , 37, 930-6	1.3	31

175	The Tyranny of the P-value: Effect Size Matters. <i>Journal of Microbiology and Biotechnology</i> , 2011 , 21, 91-92	3.3	7
174	Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic. <i>Clinical Schizophrenia and Related Psychoses</i> , 2011 , 4, 251-7	1.6	40
173	lloperidone: a clinical overview. <i>Journal of Clinical Psychiatry</i> , 2011 , 72 Suppl 1, 19-23	4.6	15
172	Number needed to treat: what it is and what it isn't, and why every clinician should know how to calculate it. <i>Journal of Clinical Psychiatry</i> , 2011 , 72, 412-3	4.6	23
171	Psychiatric Illness, Psychotropic Medication, and Childhood Obesity 2011 , 265-277		
170	Relative vs. absolute measures of benefit and risk: what's the difference?. <i>Acta Psychiatrica Scandinavica</i> , 2010 , 121, 94-102	6.5	45
169	lloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic. <i>International Journal of Clinical Practice</i> , 2010 , 64, 707-18	2.9	24
168	Citability of original research and reviews in journals and their sponsored supplements. <i>PLoS ONE</i> , 2010 , 5, e9876	3.7	5
167	Stimulant-induced trichotillomania. <i>Substance Abuse</i> , 2010 , 31, 68-70	3.8	9
166	Ziprasidone HCl capsules for the adjunctive maintenance treatment of bipolar disorder in adults. <i>Expert Review of Neurotherapeutics</i> , 2010 , 10, 1031-7	4.3	11
165	Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. <i>Postgraduate Medicine</i> , 2010 , 122, 39-48	3.7	128
164	Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities. <i>Schizophrenia Research</i> , 2010 , 119, 153-9	3.6	10
163	The importance of a good night's sleep: an open-label trial of the sodium salt of gamma-hydroxybutyric acid in insomnia associated with schizophrenia. <i>Schizophrenia Research</i> , 2010 , 120, 225-6	3.6	15
162	Authors' Submission Toolkit: a practical guide to getting your research published. <i>Current Medical Research and Opinion</i> , 2010 , 26, 1967-82	2.5	35
161	Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. <i>International Journal of Clinical Practice</i> , 2010 , 64, 216-39	2.9	67
160	Datapoints: depot antipsychotic use in New York State hospitals, 1994 to 2009. <i>Psychiatric Services</i> , 2010 , 61, 9	3.3	3
159	Introduction and Overview of the Real World Management of Schizophrenia in the Comorbid Patient. <i>CNS Spectrums</i> , 2010 , 15, 3-5	1.8	
158	lloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010 , 6, 1551-64	5.5	32

157	Spirituality, schizophrenia, and state hospitals: program description and characteristics of self-selected attendees of a spirituality therapeutic group. <i>Psychiatric Quarterly</i> , 2010 , 81, 285-92	4.1	25
156	Polypharmacy of schizophrenia. <i>Psychiatry</i> , 2010 , 7, 17-9		1
155	A review of new atypical antipsychotic launches in the United States. <i>Psychiatry</i> , 2010 , 7, 13-5		2
154	How to efficiently maintain your own electronic resource library. <i>Journal of Clinical Psychiatry</i> , 2010 , 71, 207-8	4.6	
153	Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection. <i>Patient Preference and Adherence</i> , 2009 , 3, 345-55	2.4	14
152	Egg consumption and risk of type 2 diabetes in men and women: response to Djouss[et al. <i>Diabetes Care</i> , 2009 , 32, e73; author reply e74	14.6	2
151	Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 1917-28	4	59
150	Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications. <i>Current Drug Safety</i> , 2009 , 4, 229-37	1.4	53
149	Teaching the philosophy and tools of evidence-based medicine: misunderstandings and solutions. <i>Journal of Evidence-Based Medicine</i> , 2009 , 2, 220-5	6.1	2
148	A review of tolerability and abuse liability of gamma-hydroxybutyric acid for insomnia in patients with schizophrenia. <i>Clinical Therapeutics</i> , 2009 , 31 Pt 1, 1360-73	3.5	12
147	"Stat" medication administration predicts hospital discharge. <i>Psychiatric Quarterly</i> , 2009 , 80, 65-73	4.1	4
146	Staff and patient views of the reasons for aggressive incidents: a prospective, incident-based study. <i>Psychiatric Quarterly</i> , 2009 , 80, 167-72	4.1	18
145	Using oral ziprasidone effectively: the food effect and dose-response. <i>Advances in Therapy</i> , 2009 , 26, 739-48	4.1	38
144	Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic. <i>International Journal of Clinical Practice</i> , 2009 , 63, 140-50	2.9	53
143	Teaching the philosophy and tools of evidence-based medicine: misunderstandings and solutions. <i>International Journal of Clinical Practice</i> , 2009 , 63, 353-9	2.9	7
142	Posters can be a sticking point: Letter in response to comments by Akhras et al.. <i>International Journal of Clinical Practice</i> , 2009 , 63, 963-963	2.9	
141	Systematic reviews: much ado about a lot. <i>International Journal of Clinical Practice</i> , 2009 , 63, 832-3	2.9	1
140	lloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic. <i>International Journal of Clinical Practice</i> , 2009 , 63, 1237-48	2.9	54

139	How to search and harvest the medical literature: let the citations come to you, and how to proceed when they do. <i>International Journal of Clinical Practice</i> , 2009 , 63, 1565-70	2.9	15
138	Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. <i>International Journal of Clinical Practice</i> , 2009 , 63, 1762-84	2.9	87
137	Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder. <i>Schizophrenia Research</i> , 2009 , 108, 238-44	3.6	24
136	Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials. <i>Schizophrenia Research</i> , 2009 , 111, 39-45	3.6	14
135	Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder. <i>Schizophrenia Research</i> , 2009 , 115, 115-20	3.6	16
134	Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence?. <i>Expert Review of Neurotherapeutics</i> , 2009 , 9, 55-71	4.3	63
133	GABA(B) receptors, schizophrenia and sleep dysfunction: a review of the relationship and its potential clinical and therapeutic implications. <i>CNS Drugs</i> , 2009 , 23, 681-91	6.7	50
132	Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction?. <i>Expert Review of Neurotherapeutics</i> , 2009 , 9, 1045-58	4.3	21
131	Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. <i>Schizophrenia Research</i> , 2009 , 110, 95-102	3.6	53
130	Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. <i>Journal of Clinical Psychopharmacology</i> , 2009 , 29, 278-83	1.7	62
129	Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. <i>Journal of Clinical Psychiatry</i> , 2009 , 70, 990-6	4.6	119
128	How dosing of ziprasidone in a state hospital system differs from product labeling. <i>Journal of Clinical Psychiatry</i> , 2009 , 70, 975-82	4.6	17
127	All antipsychotics are equal, but some are more equal than others. <i>Journal of Clinical Psychiatry</i> , 2009 , 70, 429-30	4.6	1
126	Adding lithium or anticonvulsants to antipsychotics for the treatment of schizophrenia: useful strategy or exercise in futility?. <i>Journal of Clinical Psychiatry</i> , 2009 , 70, 932-3	4.6	15
125	Valproate: do formulations matter?. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2008 , 33, 457; author reply 458	2.2	
124	Loss aversion in schizophrenia. <i>Schizophrenia Research</i> , 2008 , 103, 121-8	3.6	34
123	Olanzapine: review of safety 2008. <i>Expert Opinion on Drug Safety</i> , 2008 , 7, 761-9	4.1	51
122	A new rating scale for negative symptoms: the Motor-Affective-Social Scale. <i>Psychiatry Research</i> , 2008 , 160, 346-55	9.9	16

121	Antipsychotics and hyperprolactinaemia: clinical recommendations. <i>Journal of Psychopharmacology</i> , 2008 , 22, 98-103	4.6	68
120	Current guidelines and their recommendations for prolactin monitoring in psychosis. <i>Journal of Psychopharmacology</i> , 2008 , 22, 90-7	4.6	36
119	Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks. <i>Expert Review of Neurotherapeutics</i> , 2008 , 8, 1079-91	4.3	36
118	Schizophrenia, obesity, and antipsychotic medications: what can we do?. <i>Postgraduate Medicine</i> , 2008 , 120, 18-33	3.7	51
117	Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. <i>Journal of Clinical Psychopharmacology</i> , 2008 , 28, 392-400	1.7	75
116	Public-academic partnerships: integrating state psychiatric hospital treatment and clinical research. <i>Psychiatric Services</i> , 2008 , 59, 958-60	3.3	4
115	Did CATIE influence antipsychotic use?. <i>Psychiatric Services</i> , 2008 , 59, 476	3.3	4
114	Reducing inpatient aggression: does paying attention pay off?. <i>Psychiatric Quarterly</i> , 2008 , 79, 91-5	4.1	11
113	Compelling or irrelevant? Using number needed to treat can help decide. <i>Acta Psychiatrica Scandinavica</i> , 2008 , 117, 412-9	6.5	121
112	Interpreting and applying the EUFEST results using number needed to treat: antipsychotic effectiveness in first-episode schizophrenia. <i>International Journal of Clinical Practice</i> , 2008 , 62, 837-40	2.9	7
111	Heterogeneity of violence in schizophrenia and implications for long-term treatment. <i>International Journal of Clinical Practice</i> , 2008 , 62, 1237-45	2.9	115
110	Paliperidone: the evidence of its therapeutic value in schizophrenia. <i>Core Evidence</i> , 2008 , 2, 261-71	4.9	12
109	Antiepileptics in the Treatment of Schizophrenia. <i>Medical Psychiatry</i> , 2008 , 187-206		1
108	Atypical antipsychotics, elderly patients, and mortality risk. <i>Southern Medical Journal</i> , 2007 , 100, 964-5	0.6	5
107	Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. <i>CNS Neuroscience & Therapeutics</i> , 2007 , 13, 137-77		61
106	Paliperidone: quo vadis?. <i>International Journal of Clinical Practice</i> , 2007 , 61, 653-62	2.9	29
105	The Treatment of Acute Agitation in Schizophrenia. <i>CNS Spectrums</i> , 2007 , 12, 1-16	1.8	3
104	Show me the evidence: using number needed to treat. <i>Southern Medical Journal</i> , 2007 , 100, 881-4	0.6	23

103	Datapoints: The ups and downs of dosing second-generation antipsychotics. <i>Psychiatric Services</i> , 2007 , 58, 11	3.3	12
102	Pharmacokinetics of aripiprazole and concomitant carbamazepine. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 279-83	1.7	36
101	Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 582-9	1.7	88
100	Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. <i>International Clinical Psychopharmacology</i> , 2007 , 22, 356-62	2.2	38
99	The role of adherence to medication in the effectiveness of long-term treatment of schizophrenia. <i>European Psychiatry</i> , 2007 , 22, S54-S55	6	2
98	Reviewing CATIE for clinicians: balancing benefit and risk using evidence-based medicine tools. <i>Current Medical Research and Opinion</i> , 2007 , 23, 2551-7	2.5	14
97	Interpreting and Applying the CATIE Results: With CATIE, context is key, when sorting out Phases 1, 1A, 1B, 2E, and 2T. <i>Psychiatry</i> , 2007 , 4, 23-9		2
96	Impact factor? Shmimpact factor!: the journal impact factor, modern day literature searching, and the publication process. <i>Psychiatry</i> , 2007 , 4, 54-7		3
95	The psychopharmacology of violence with emphasis on schizophrenia, part 1: acute treatment. <i>Journal of Clinical Psychiatry</i> , 2007 , 68, 163-4	4.6	3
94	The psychopharmacology of violence with emphasis on schizophrenia, part 2: long-term treatment. <i>Journal of Clinical Psychiatry</i> , 2007 , 68, 331-2	4.6	2
93	Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. <i>Journal of Clinical Psychiatry</i> , 2007 , 68, 1876-85	4.6	89
92	Introduction: weighing the evidence: weight management insights for treating major mental illness. <i>Journal of Clinical Psychiatry</i> , 2007 , 68 Suppl 12, 4	4.6	
91	The effectiveness criterion: balancing efficacy against the risks of weight gain. <i>Journal of Clinical Psychiatry</i> , 2007 , 68 Suppl 12, 12-7	4.6	4
90	Maintenance treatment with olanzapine reduces relapse in people with bipolar I disorder who have responded to acute olanzapine treatment. <i>Evidence-Based Mental Health</i> , 2006 , 9, 73	11.1	
89	Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. <i>Archives of General Psychiatry</i> , 2006 , 63, 622-9		248
88	Are we treating schizophrenia effectively? Understanding the primary outcomes of the CATIE study. <i>CNS Spectrums</i> , 2006 , 11, 1-13; quiz 14	1.8	5
87	Incidence, prevalence, and surveillance for diabetes in New York State psychiatric hospitals, 1997-2004. <i>Psychiatric Services</i> , 2006 , 57, 1132-9	3.3	17
86	Early predictors of substantial weight gain in bipolar patients treated with olanzapine. <i>Journal of Clinical Psychopharmacology</i> , 2006 , 26, 316-20	1.7	51

85	Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2006 , 26, 632-7	1.7	24
84	Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?. <i>International Journal of Clinical Practice</i> , 2006 , 60, 933-40	2.9	36
83	A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2006 , 2, 427-43	3.1	38
82	Efficacy of ziprasidone against hostility in schizophrenia: Post hoc analysis of randomized, open-label study data. <i>Journal of Clinical Psychiatry</i> , 2006 , 67, 638-42	4.6	29
81	Monotherapy versus polypharmacy for hospitalized psychiatric patients. <i>American Journal of Psychiatry</i> , 2005 , 162, 631; author reply 632-3	11.9	9
80	Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia. <i>European Neuropsychopharmacology</i> , 2005 , 15, 525-31	1.2	52
79	Do guidelines for severe mental illness promote physical health and well-being?. <i>Journal of Psychopharmacology</i> , 2005 , 19, 102-9	4.6	83
78	Pharmacokinetics of aripiprazole and concomitant lithium and valproate. <i>Journal of Clinical Pharmacology</i> , 2005 , 45, 89-93	2.9	62
77	The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. <i>Neuroscience Letters</i> , 2005 , 379, 81-9	3.3	82
76	Identification of a naturally occurring 21 bp deletion in alpha 2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment. <i>Pharmacological Research</i> , 2005 , 51, 381-4	10.2	8
75	Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation. <i>Schizophrenia Research</i> , 2005 , 76, 127-9	3.6	5
74	Best clinical practice with ziprasidone IM: update after 2 years of experience. <i>CNS Spectrums</i> , 2005 , 10, 1-15	1.8	31
73	Dosing of second-generation antipsychotic medication in a state hospital system. <i>Journal of Clinical Psychopharmacology</i> , 2005 , 25, 388-91	1.7	27
72	Focus on the clinical ramifications of antipsychotic choice for the risk for developing type 2 diabetes mellitus. <i>International Journal of Neuropsychopharmacology</i> , 2005 , 8, 147-51	5.8	5
71	Commentary: bipolar disorder is a potentially fatal disease. <i>Postgraduate Medicine</i> , 2005 , 117, 9-11	3.7	3
70	The many faces of bipolar disorder. How to tell them apart. <i>Postgraduate Medicine</i> , 2005 , 117, 15-6, 19-23, 7	3.7	10
69	Latest therapies for bipolar disorder. Looking beyond lithium. <i>Postgraduate Medicine</i> , 2005 , 117, 25-6, 29-32, 35-6	3.7	18
68	Testing for diabetes. <i>British Journal of Psychiatry</i> , 2005 , 186, 78	5.4	4

67	Toward convergence in the medication treatment of bipolar disorder and schizophrenia. <i>Harvard Review of Psychiatry</i> , 2005 , 13, 28-42	4.1	21
66	Metabolic syndrome and cardiovascular disease. <i>Journal of Psychopharmacology</i> , 2005 , 19, 84-93	4.6	70
65	Diabetes and schizophrenia 2005: are we any closer to understanding the link?. <i>Journal of Psychopharmacology</i> , 2005 , 19, 56-65	4.6	75
64	Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. <i>Journal of Clinical Psychiatry</i> , 2005 , 66, 1073-4	4.6	13
63	Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies. <i>Journal of Clinical Psychiatry</i> , 2005 , 66, 1362-6	4.6	27
62	Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies. <i>Journal of Clinical Psychiatry</i> , 2005 , 66, 1512-6	4.6	44
61	Metabolic issues in patients with severe mental illness. <i>Southern Medical Journal</i> , 2005 , 98, 714-20	0.6	36
60	The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning. <i>Postgraduate Medicine</i> , 2004 , 116, 49-51, 55-9, 63	3.7	18
59	Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. <i>Psychiatric Services</i> , 2004 , 55, 1006-13	3.3	88
58	Flexible oral olanzapine dosing in acutely agitated people is immediately effective in reducing symptoms. <i>Evidence-Based Mental Health</i> , 2004 , 7, 12	11.1	
57	Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. <i>Diabetes Care</i> , 2004 , 27, 2087-8; author reply 2089-90	14.6	14
56	New treatments for agitation. <i>Psychiatric Quarterly</i> , 2004 , 75, 197-213	4.1	28
55	COMT158 polymorphism and hostility. <i>American Journal of Medical Genetics Part A</i> , 2004 , 127B, 28-9		24
54	Ziprasidone versus haloperidol for the treatment of agitation. <i>Annals of Emergency Medicine</i> , 2004 , 44, S22	2.1	7
53	Re: treatment noncompliance with orally disintegrating olanzapine tablets. <i>Canadian Journal of Psychiatry</i> , 2004 , 49, 412-3; author reply 413	4.8	3
52	A study of the safety, efficacy, and tolerability of switching from the standard delayed release preparation of divalproex sodium to the extended release formulation in patients with schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2004 , 24, 255-9	1.7	14
51	Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. <i>Psychiatric Services</i> , 2004 , 55, 290-4	3.3	111
50	Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. <i>Journal of Clinical Psychopharmacology</i> , 2004 , 24, 225-8	1.7	126

49	Antihostility Effects of Adjunctive Divalproex. <i>Psychiatric Services</i> , 2004 , 55, 1068-a-1069	3.3	
48	Overt Aggression and Psychotic Symptoms in Patients With Schizophrenia Treated With Clozapine, Olanzapine, Risperidone, or Haloperidol. <i>Journal of Clinical Psychopharmacology</i> , 2004 , 24, 1-4	1.7	3
47	Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. <i>Journal of Clinical Psychiatry</i> , 2004 , 65, 57-61	4.6	109
46	Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2004 , 65, 551-6	4.6	44
45	Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. <i>American Journal of Psychiatry</i> , 2003 , 160, 290-6	11.9	379
44	Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. <i>American Journal of Psychiatry</i> , 2003 , 160, 1117-24	11.9	55
43	Use of mood stabilizers among patients with schizophrenia, 1994-2001. <i>Psychiatric Services</i> , 2002 , 53, 1212	3.3	37
42	Atypical antipsychotics for acute agitation. New intramuscular options offer advantages. <i>Postgraduate Medicine</i> , 2002 , 112, 85-8, 94-6	3.7	29
41	Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. <i>American Journal of Psychiatry</i> , 2002 , 159, 255-62	11.9	335
40	Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. <i>American Journal of Psychiatry</i> , 2002 , 159, 1018-28	11.9	448
39	Managing treatment-resistant schizophrenia: evidence from randomized clinical trials. <i>Journal of Psychiatric Practice</i> , 2002 , 8, 205-15	1.3	17
38	Antipsychotic-induced weight gain and therapeutic response: a differential association. <i>Journal of Clinical Psychopharmacology</i> , 2002 , 22, 244-51	1.7	117
37	Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. <i>Biological Psychiatry</i> , 2002 , 52, 701-7	7.9	286
36	Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. <i>Harvard Review of Psychiatry</i> , 2002 , 10, 280-91	4.1	63
35	Atypical antipsychotics: revolutionary or incremental advance?. <i>Expert Review of Neurotherapeutics</i> , 2002 , 2, 69-88	4.3	21
34	Optimizing dosing in atypical neuroleptic monotherapy. <i>Dialogues in Clinical Neuroscience</i> , 2002 , 4, 438-437	4.7	1
33	Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. <i>Journal of Clinical Psychiatry</i> , 2002 , 63, 931-5	4.6	40
32	Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. <i>Psychiatric Services</i> , 2001 , 52, 1510-4	3.3	149

31	Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial. <i>Journal of Clinical Psychopharmacology</i> , 2001 , 21, 448-53	1.7	26
30	Antiaggressive effect of quetiapine in a patient with schizoaffective disorder. <i>Journal of Clinical Psychiatry</i> , 2001 , 62, 901	4.6	11
29	Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. <i>Psychiatric Services</i> , 2000 , 51, 634-8	3.3	94
28	FC09.05 Clozapine, olanzapine, risperidone, and haloperidol in refractory schizophrenia. <i>European Psychiatry</i> , 2000 , 15, 284s-284s	6	5
27	Management of Violence in Schizophrenia. <i>Psychiatric Annals</i> , 2000 , 30, 41-52	0.5	15
26	Pharmacological Interventions for Preventing Violence Among the Mentally Ill with Co-Occurring Personality Disorders 2000 , 193-209		1
25	Violent patients in the emergency setting. <i>Psychiatric Clinics of North America</i> , 1999 , 22, 789-801	3.1	40
24	Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns. <i>Schizophrenia Research</i> , 1999 , 35 Suppl, S23-33	3.6	43
23	Violence in Schizophrenia. <i>Journal of Psychiatric Practice</i> , 1999 , 5, 326-335	1.3	4
22	Schizophrenia: violence and comorbidity. <i>Current Opinion in Psychiatry</i> , 1999 , 12, 47-51	4.9	10
21	Utilization of valproate: extent of inpatient use in the New York State Office of Mental Health. <i>Psychiatric Quarterly</i> , 1998 , 69, 283-300	4.1	34
20	Practice protocols, parameters, pathways, and guidelines: a review. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 1998 , 25, 257-69	3.1	5
19	Safety of Accutane with possible depression. <i>Postgraduate Medicine</i> , 1998 , 104, 38	3.7	10
18	New antipsychotic medications: what advantages do they offer?. <i>Postgraduate Medicine</i> , 1997 , 101, 207-10, 213-4	3.7	14
17	Layoffs, reductions-in-force, downsizing, rightsizing: the case of a state psychiatric hospital. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 1997 , 24, 523-33	3.1	
16	Psychopharmacology of Violence: Part I: Assessment and Acute Treatment. <i>Psychiatric Annals</i> , 1997 , 27, 691-695	0.5	12
15	Psychopharmacology of Violence: Part II: Beyond the Acute Episode. <i>Psychiatric Annals</i> , 1997 , 27, 696-703	0.5	16
14	Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients. <i>Journal of Clinical Psychiatry</i> , 1996 , 57, 455-9	4.6	21

13	Utilization of depot neuroleptic medication in psychiatric inpatients. <i>Psychopharmacology Bulletin</i> , 1996 , 32, 321-6	0.9	27
12	Clinical and administrative consequences of a reduced census on a psychiatric intensive care unit. <i>Psychiatric Quarterly</i> , 1995 , 66, 209-17	4.1	3
11	Personal computers in risk management and incident reporting. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 1995 , 22, 511-519	3.1	1
10	Use of lithium, carbamazepine, and valproic acid in a state-operated psychiatric hospital. <i>Journal of Pharmacy Technology</i> , 1995 , 11, 55-9	0.6	24
9	Management of depression. <i>Postgraduate Medicine</i> , 1994 , 95, 137-145	3.7	6
8	Length of stay and recidivism on a psychiatric intensive care unit. <i>Psychiatric Services</i> , 1994 , 45, 74-6	3.3	7
7	Management of depression. Current options for this highly treatable disorder. <i>Postgraduate Medicine</i> , 1994 , 95, 137-42, 45	3.7	1
6	The dangerous agitated patient. What to do right now. <i>Postgraduate Medicine</i> , 1990 , 87, 231-6	3.7	11
5	A double-blind, placebo-controlled study of adjunctive nadolol in the management of violent psychiatric patients. <i>Psychopharmacology Bulletin</i> , 1990 , 26, 367-71	0.9	20
4	Differential diagnosis of psychosis. A brief guide for the primary care physician. <i>Postgraduate Medicine</i> , 1989 , 85, 273-4, 279-80	3.7	8
3	Psychopharmacology of Violence 645-653		
2	Pharmacologic Treatment of Agitation 200-218		1
1	Dissemination of clinical trial information: multiple audiences, multiple formats 169-176		